I promise. Alexander Green and I are not in cahoots about the coming boom in corporate takeovers… We both researched the possibility separately. Unprompted, I might add. And yet, armed with different evidence, we arrived at the same conclusion. If you ask me, such a convergence of analysis in a narrow space of time shouldn’t be ignored. So today, let’s move on from why a takeover boom is imminent and focus exclusively on three takeover targets you can profit from…

A more recent addition to my transformational technologies portfolio, Medarex (NASDAQ:MEDX), has scored a huge win. The company, along with Massachusetts Biologic Laboratory, will get $60 million upfront from Merck (NYSE:MRK) for license rights to a monoclonal antibody that apparently cures C. difficile infection. They are eligible for another $165 million in milestones as well as royalties.

In the past few years, a strange new “defensive” asset has appeared in the market.

Investors use the “defensive” label to describe businesses that enjoy steady demand for their products – like food, cigarettes and electric utilities.

Biotech is no longer just a drugs game.